145P Characterising homologous recombination deficiencies in gliomas
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Recurrent gliomas, whether isocitrate dehydrogenase (IDH) mutant or wildtype, have limited effective treatments, supporting evaluation of biomarker-guided therapies. IDH mutations drive accumulation of 2-hydroxyglutarate, creating vulnerability within DNA damage response pathways by inducing homologous recombination deficiency (HRD). In preclinical models, HRD has been associated with sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition and appears reversible with IDH inhibition. Accurate characterisation of HRD in gliomas may inform its utility as a therapeutic biomarker.
Fields of Study & Subjects
Glioma Diagnosis and Treatment
PARP inhibition in cancer therapy
Chromatin Remodeling and Cancer
Publication details
- Journal / source
- ESMO Open
- Volume
- 11
- Pages
- 106288–106288
- Publication date
- 1 April 2026
- Language
- EN